Details
Stereochemistry | ACHIRAL |
Molecular Formula | C3H3BrO3 |
Molecular Weight | 166.958 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)C(=O)CBr
InChI
InChIKey=PRRZDZJYSJLDBS-UHFFFAOYSA-N
InChI=1S/C3H3BrO3/c4-1-2(5)3(6)7/h1H2,(H,6,7)
Molecular Formula | C3H3BrO3 |
Molecular Weight | 166.958 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Bromopyruvate is an halogenated analogue of pyruvic acid known as an alkylating agent reacting with thiol groups of many proteins. Bromopyruvate exerts anticancer action. It is based on the impairment of energy metabolism of tumor cells by inhibiting enzymes in the glycolysis pathway (hexokinase II, glyceraldehyde 3-phosphate dehydrogenase, phosphoglycerate kinase) and the oxidative phosphorylation (succinate dehydrogenase). Bromopyruvate induces endoplasmic reticulum stress, inhibits global protein synthesis further contributing to cancer cell death. Treatment with bromopyruvate has been administered in several cancer type models both in vitro and in vivo, either alone or in combination with other anticancer therapeutic approaches. These studies clearly demonstrate bromopyruvate broad action against multiple cancer types. This compound has also antifungal and antiparasitic activity.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: 3662629.0 Gene Symbol: Tb10.6k15.3850 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8429041 |
2.67 µM [IC50] | ||
Target ID: O00187|||Q9H498 Gene ID: 10747.0 Gene Symbol: MASP2 Target Organism: Homo sapiens (Human) Sources: https://adisinsight.springer.com/drugs/800038438 |
|||
Target ID: GO:0045254 | pyruvate dehydrogenase complex Sources: https://adisinsight.springer.com/drugs/800038438 |
PubMed
Title | Date | PubMed |
---|---|---|
Inactivation of H+-vacuolar ATPase by the energy blocker 3-bromopyruvate, a new antitumour agent. | 2006 Oct 19 |
|
The cancer cell's "power plants" as promising therapeutic targets: an overview. | 2007 Feb |
|
Metabolic oxidative stress elicited by the copper(II) complex [Cu(isaepy)2] triggers apoptosis in SH-SY5Y cells through the induction of the AMP-activated protein kinase/p38MAPK/p53 signalling axis: evidence for a combined use with 3-bromopyruvate in neuroblastoma treatment. | 2011 Aug 1 |
|
MCT1-mediated transport of a toxic molecule is an effective strategy for targeting glycolytic tumors. | 2013 Jan |
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 19:52:53 GMT 2025
by
admin
on
Mon Mar 31 19:52:53 GMT 2025
|
Record UNII |
63JMV04GRK
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Systematic Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
FDA ORPHAN DRUG |
894722
Created by
admin on Mon Mar 31 19:52:53 GMT 2025 , Edited by admin on Mon Mar 31 19:52:53 GMT 2025
|
||
|
FDA ORPHAN DRUG |
390013
Created by
admin on Mon Mar 31 19:52:53 GMT 2025 , Edited by admin on Mon Mar 31 19:52:53 GMT 2025
|
||
|
FDA ORPHAN DRUG |
430514
Created by
admin on Mon Mar 31 19:52:53 GMT 2025 , Edited by admin on Mon Mar 31 19:52:53 GMT 2025
|
||
|
FDA ORPHAN DRUG |
736920
Created by
admin on Mon Mar 31 19:52:53 GMT 2025 , Edited by admin on Mon Mar 31 19:52:53 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
70684
Created by
admin on Mon Mar 31 19:52:53 GMT 2025 , Edited by admin on Mon Mar 31 19:52:53 GMT 2025
|
PRIMARY | |||
|
11731
Created by
admin on Mon Mar 31 19:52:53 GMT 2025 , Edited by admin on Mon Mar 31 19:52:53 GMT 2025
|
PRIMARY | |||
|
Bromopyruvate
Created by
admin on Mon Mar 31 19:52:53 GMT 2025 , Edited by admin on Mon Mar 31 19:52:53 GMT 2025
|
PRIMARY | |||
|
C017092
Created by
admin on Mon Mar 31 19:52:53 GMT 2025 , Edited by admin on Mon Mar 31 19:52:53 GMT 2025
|
PRIMARY | |||
|
62343
Created by
admin on Mon Mar 31 19:52:53 GMT 2025 , Edited by admin on Mon Mar 31 19:52:53 GMT 2025
|
PRIMARY | |||
|
DTXSID7040940
Created by
admin on Mon Mar 31 19:52:53 GMT 2025 , Edited by admin on Mon Mar 31 19:52:53 GMT 2025
|
PRIMARY | |||
|
214-206-5
Created by
admin on Mon Mar 31 19:52:53 GMT 2025 , Edited by admin on Mon Mar 31 19:52:53 GMT 2025
|
PRIMARY | |||
|
100000177177
Created by
admin on Mon Mar 31 19:52:53 GMT 2025 , Edited by admin on Mon Mar 31 19:52:53 GMT 2025
|
PRIMARY | |||
|
1113-59-3
Created by
admin on Mon Mar 31 19:52:53 GMT 2025 , Edited by admin on Mon Mar 31 19:52:53 GMT 2025
|
PRIMARY | |||
|
63JMV04GRK
Created by
admin on Mon Mar 31 19:52:53 GMT 2025 , Edited by admin on Mon Mar 31 19:52:53 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TRANSPORTER -> SUBSTRATE |
Expression higher in tumor cells
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|